Intensidad de dosis relativa en pacientes con cáncer tratados con quimioterapia.

Relative dose intensity (RDI) in patients with cancer treated with chemotherapy.

Contenido principal del artículo

Pedro Luis Ramos Guette

Descargas

Los datos de descargas todavía no están disponibles.

Detalles del artículo

Biografía del autor/a (VER)

Pedro Luis Ramos Guette, Clínica Oncocare

Medicina interna, oncología, epidemiología. Clínica Oncocare.

Referencias (VER)

Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst. 1998;90(16):1205-11.

Chang J. Chemotherapy dose reduction and delay in clinical practice. Evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer. 2000;36 Suppl 1:S11-4.

Wood WC, Budman DR, Korzum AH, Cooper MR, Younger J, Hart RD, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med. 1994;330(18):1253-9.

Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984;2(11):1281-8.

Hryniuk W, Frei E 3rd, Wright FA. A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity. J Clin Oncol. 1998;16(9):3137-47.

Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol. 1986;4(8):1162-70.

Berg J. Dose intensity in patients with metastatic breast cancer--time for novel thoughts? Ann Oncol. 1997;8(2):109-10.

Hryniuk W, Goodyear M. The calculation or received dose intensity. J Clin Oncol. 1990;8:1935-37.

Hamilton A, Hortobagyi G. Chemotherapy: what progress in the last 5 years? J Clin Oncol. 2005;23(8):1760-75.

Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of followup. N Engl J Med. 1995;332(14):901-6.

Berry DA, Budman DR. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst. 1999;91 (16):1425A-1425.

Shayne M, Crawford J, Dale DC, CulaKova E, Lyman GH; ANC Study Group. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat. 2006;100 (3):255-62.

Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21 (24):4524-31.

Piccart MJ, Biganzoli L, Di Leo A. The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned? Eur J Cancer. 2000;36 Suppl 1:S4-10.

Hurria A, Mohile S, Gajra A, Klepin H, Muss H, Chapman A, et al. Validation of a prediction tool for chemotherapy toxicity in older adults with cancer. J Clin Oncol. 2016;34 (20):2366-71.

Pérez J, Cholvi M, Almela M, Borrás C, Almenar D, Jiménez N.Análisis de la intensidad de dosis y la adhesión de los esquemas de quimioterapia adyuvante en pacientes con cáncer de mama.Atención Farmacéutica. 2000;2:211-8.

Ziegler J, Citron M. Dose-dense adjuvant chemotherapy for breast cancer. Cancer Nurs. 2006;29(4):266-72.

Citado por